http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-533227-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02d2b7b5831d88d46035d44c54256fb0 |
| filingDate | 2001-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc6a8ec8f7cc814e9bd9fbeab033d456 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac35e4e8ce26282613f7df8e05fd7376 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd0a9273e97414aa2733637fa3910451 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc194fd0177c08a86c98662aee9222ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c262a78e8a124317ee99c81d537f5201 |
| publicationDate | 2006-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-533227-A |
| titleOfInvention | Benzoisothiazole based compounds as muscarinic agents |
| abstract | Benzoisothiazole compounds of formula (I), their pharmaceutically acceptable salts, esters and prodrugs thereof are disclosed: wherein: Z1 is CR1, Z2 is CR2, Z3 is CR3 and Z4 is CR4; W1 is S, W2 is N and W3 is CG; wherein G and R1 to R4 are as described in the specification. These compounds are agonists of cholinergic receptors including muscarinic receptors, especially the m1 and m4 subtype of muscarinic receptors, also disclosed are the methods of using the provided compounds for modulating conditions associated with cholinergic receptors, especially for treating or alleviating disease conditions associated with muscarinic receptors, e. g., m1 or m4 subtypes of receptors. |
| priorityDate | 2000-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 238.